Two new, powerful small molecules may be able to kill cancers that other therapies can't

June 15, 2020

DUARTE, Calif. -- City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance.

Called CS1 (or bisantrene) and CS2 (or brequinar), these cancer inhibitor compounds are part of a protein known as "fat mass and obesity-associated protein." Nicknamed FTO, the protein plays a critical role in cancer development and progression, primarily because it regulates cancer stem cells and immune evasion. In other words, FTO promotes the growth, self-renewal, metastasis and immune escape of cancer cells.

"The cancer inhibitors we developed are at least 10 times more effective in killing acute myeloid leukemia cells than several previously reported FTO inhibitors," said Jianjun Chen, Ph.D., the Simms/Mann Family Foundation Chair in Systems Biology at City of Hope and corresponding author of the new study. "In the near future, we should use these two compounds alone or in combination with other therapeutic agents such as targeted therapy, standard chemotherapy, immunotherapy or radiotherapy to treat patients with FTO-high cancers."

Examples of FTO-high cancers include acute myeloid leukemia (AML), an aggressive brain cancer called glioblastoma, pancreatic cancer and breast cancer. The study, published in the journal Cancer Cell on June 11, provides new insight into how cancer stem cells replenish and visibility into how cancer evades our immune system. It highlights the possibility that targeting FTO with potent inhibitors could eventually become a treatment for certain cancers.

In the study, City of Hope scientists demonstrated that the two new FTO inhibitor compounds they created had potent anti-tumor effects and substantially improved overall survival in mice with AML or a solid tumor such as breast cancer.

An estimated 11,200 people are expected to die due to AML in 2020. The five-year survival rate is 29%, according to National Institutes of Health SEER data. Breast cancer is the second most common cancer among U.S. women.

Chen and his colleagues saw the need to address these big problems. The Chen lab has been conducting research on RNA modification in cancer for eight years and is a pioneer in this field -- developing personalized treatments that will enable the practice of precision medicine. The lab began working on the CS1 and CS2 project three years ago when Chen first arrived at City of Hope.

Chen's team noted that many cancer patients either do not respond to treatments that are currently available such as chemotherapy, targeted therapy or immunotherapy, or that they responded to the therapeutics in the beginning but relapse later due to cancer-regenerating stem cells and the escape of cancer cells from our immune surveillance.

It turns out that modifying FTO or using small molecules to inhibit FTO interrupts the supply chain that enables cancer to develop and progress. Studies showed that treatment with a relatively low dose of CS1 or CS2 (5 mg/kg/day 10 times every other day) could, at the very least, double the median survival in mouse models with AML. CS1 became more potent after Chen's lab put a sort of sleeve over it so that it could bypass certain barriers that do not like water-based molecules.

"Our study suggests that combining FTO inhibitor treatment with other therapies will improve patient outcomes because this method will eradicate cancer stem cells and mechanisms that suppress the immune system," said Rui Su, Ph.D., lead author of the study and assistant research professor in the Department of Systems Biology at the Beckman Research Institute of City of Hope.

CS1 and CS2 prevent FTO from connecting with target messenger RNAs, including cancer-causing genes MYC and CEBPA, as well as immune checkpoint gene LILRB4.

Because CS1 (bisantrene) and CS2 (brequinar) have been tested in multiple clinical trials under the guises of other objectives, Chen and his colleagues believe this basic research has access to a freeway entrance that will fast track it into clinical trials. The National Institutes of Health (NIH) has already funded the next step: The Chen lab is working to further optimize CS1 and CS2 to develop improved FTO inhibitor compounds that are more efficacious with minimal side effects for humans.
Scientists from Harvard Medical School, China Medical University, Cincinnati Children's Hospital Medical Center, The First Affiliated Hospital of Sun Yat-sen University, Tianjin University, the Shanghai branch of the Chinese Academy of Sciences, Houston Methodist, The First Affiliated Hospital of Zhejiang University, Midwestern University and Shanghai Jiao Tong University School of Medicine also contributed to this research. The study used the Hematopoietic Tissue Biorepository core at City of Hope, which is supported by the National Cancer Institute of the NIH (P30CA33572). Other supporters include NIH grants (R01 CA243386, R01 CA214965, R01 CA236399, R01 CA211614, R01 DK124116, R50CA211404, R35CA197628, U10CA180827, R01CA137060, R01CA157644, R01CA172558 and R01CA213138), The Margaret E. Early Medical Research Trust, and American Cancer Society Cancer Research Scholar grant.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope's translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is the highest ranked cancer hospital in the West, according to U.S. News & World Report's Best Hospitals: Specialty Ranking. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

City of Hope

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to